Answer Regarding: Potent P2Y12 Inhibitors and Bleeding Complications

Turk Kardiyol Dern Ars. 2022 Oct;50(7):545-546. doi: 10.5543/tkda.2022.220922.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acute Coronary Syndrome*
  • Clopidogrel
  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors
  • Prasugrel Hydrochloride
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Clopidogrel
  • Prasugrel Hydrochloride